124
Participants
Start Date
May 31, 2001
Primary Completion Date
February 28, 2006
Study Completion Date
February 28, 2006
A.1 Lucinactant
3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
B.3 SoC
Standard ARDS management and ICU care
A.2 Lucinactant
3 30 mL aliquots at a concentration of 10 mg/mL each
A.3 Lucinactant
2 50 mL aliquots at concentrations of 10 and 20 mg/mL
A.4 Lucinactant
2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
B.1 Lucinactant
2 50 mL aliquots at concentrations of 10 and 20 mg/mL
B.2 Lucinactant
2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
Discovery Laboratories, Inc., Warrington
Lead Sponsor
Windtree Therapeutics
INDUSTRY